[go: up one dir, main page]

WO2012060791A3 - Production method for pharmaceutical compositions comprising cefdinir - Google Patents

Production method for pharmaceutical compositions comprising cefdinir Download PDF

Info

Publication number
WO2012060791A3
WO2012060791A3 PCT/TR2011/000256 TR2011000256W WO2012060791A3 WO 2012060791 A3 WO2012060791 A3 WO 2012060791A3 TR 2011000256 W TR2011000256 W TR 2011000256W WO 2012060791 A3 WO2012060791 A3 WO 2012060791A3
Authority
WO
WIPO (PCT)
Prior art keywords
cefdinir
production method
pharmaceutical compositions
preparation
active agent
Prior art date
Application number
PCT/TR2011/000256
Other languages
French (fr)
Other versions
WO2012060791A2 (en
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2012060791A2 publication Critical patent/WO2012060791A2/en
Publication of WO2012060791A3 publication Critical patent/WO2012060791A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a production method to be used for preparation of pharmaceutical dosage forms comprising cefdinir as the active agent.
PCT/TR2011/000256 2010-11-05 2011-11-03 Production method for pharmaceutical compositions comprising cefdinir WO2012060791A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/09166 2010-11-05
TR2010/09166A TR201009166A2 (en) 2010-11-05 2010-11-05 Production method for cefdinir-containing pharmaceutical composition

Publications (2)

Publication Number Publication Date
WO2012060791A2 WO2012060791A2 (en) 2012-05-10
WO2012060791A3 true WO2012060791A3 (en) 2012-07-26

Family

ID=45524933

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000256 WO2012060791A2 (en) 2010-11-05 2011-11-03 Production method for pharmaceutical compositions comprising cefdinir

Country Status (2)

Country Link
TR (1) TR201009166A2 (en)
WO (1) WO2012060791A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013095313A1 (en) * 2011-12-19 2013-06-27 Mahmut Bilgic Pharmaceutical formulations comprising cefdinir
CN102935075B (en) * 2012-11-22 2014-02-19 海南三叶美好制药有限公司 Cefdinir capsule and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070128268A1 (en) * 2005-12-07 2007-06-07 Herwig Jennewein Pharmaceutical compositions comprising an antibiotic
US20070134325A1 (en) * 1996-02-29 2007-06-14 Astellas Pharma Inc. Beta-lactam antibiotic-containing tablet and production thereof
WO2007125541A1 (en) * 2006-05-01 2007-11-08 Lupin Limited Pharmaceutical compositions of cefdinir
CN101264085A (en) * 2007-03-14 2008-09-17 南京师范大学 Pharmaceutical composition containing cefdinir cyclodextrin inclusion complex and preparation method thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA836918B (en) 1982-09-30 1984-05-30 Fujisawa Pharmaceutical Co 7-substituted-3-vinyl-3-cephem compounds and processes for the production of the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070134325A1 (en) * 1996-02-29 2007-06-14 Astellas Pharma Inc. Beta-lactam antibiotic-containing tablet and production thereof
US20070128268A1 (en) * 2005-12-07 2007-06-07 Herwig Jennewein Pharmaceutical compositions comprising an antibiotic
WO2007125541A1 (en) * 2006-05-01 2007-11-08 Lupin Limited Pharmaceutical compositions of cefdinir
CN101264085A (en) * 2007-03-14 2008-09-17 南京师范大学 Pharmaceutical composition containing cefdinir cyclodextrin inclusion complex and preparation method thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PRESCOTT J K ET AL: "On powder flowability", PHARMACEUTICAL TECHNOLOGY 2000 US, vol. 24, no. 10, 2000, pages 60 - 84+236, XP002677114, ISSN: 0147-8087 *

Also Published As

Publication number Publication date
TR201009166A2 (en) 2012-05-21
WO2012060791A2 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
WO2010092090A3 (en) Novel salts of sitagliptin
WO2014014835A3 (en) Criystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
WO2011093825A3 (en) Effervescent dosage forms comprising cephalosporin antibiotic
WO2011130615A3 (en) Preparation of lacosamide
WO2012021715A3 (en) Stable formulations of linaclotide
ZA201206254B (en) Novel salts for the manufacture of pharmaceutical compositions
WO2011157721A3 (en) Ivabradine-containing pharmaceutical composition
WO2011017502A3 (en) Linaclotide-containing formulations for oral administration
EA029539B8 (en) Pharmaceutical composition of sitagliptin
MX2014010433A (en) Novel crystalline form of sitagliptin sulfate.
WO2012037562A3 (en) Pharmaceutical and nutraceutical compositions of abscisic acid
WO2012070062A3 (en) Novel polymorph of nilotinib hydrochloride
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
WO2014068586A3 (en) Solid oral compositions of tolvaptan
WO2013128379A3 (en) Crystalline polymorphic forms of linagliptin
WO2012155226A8 (en) Method for producing pyrostegia venusta derivatives, pyrostegia venusta derivatives, pharmaceutical compositions and uses thereof
WO2011139249A3 (en) Pharmaceutical composition comprising cefdinir
MX2013012773A (en) Drug substances, pharmeceutical compositions and methods for preparing the same.
WO2011095985A3 (en) Rasagiline salts and processes for the preparation thereof
WO2012060791A3 (en) Production method for pharmaceutical compositions comprising cefdinir
WO2011157670A3 (en) Process for the preparation of benzamide derivatives
WO2012150607A3 (en) Oral liquid composition comprising divalproex sodium and process for preparing thereof
WO2012007758A3 (en) Pharmaceutical formulations
WO2011107921A3 (en) Modified release composition of milnacipran

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11811438

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11811438

Country of ref document: EP

Kind code of ref document: A2